Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Hepatitis C

  Free Subscription


Articles published in J Hepatol

Retrieve available abstracts of 193 articles:
HTML format
Text format



Single Articles


    October 2019
  1. VRANCKEN B, Cuypers L, Perez AB, Chueca N, et al
    Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes.
    J Hepatol. 2019 Oct 1. pii: S0168-8278(19)30476.
    PubMed     Text format    


    August 2019
  2. CHILDS K, Davis C, Cannon M, Montague S, et al
    Suboptimal SVR rates in African patients with atypical Genotype 1 subtypes: implications for global elimination of Hepatitis C.
    J Hepatol. 2019 Aug 7. pii: S0168-8278(19)30468.
    PubMed     Text format     Abstract available


  3. DEGASPERI E, Spinetti A, Lombardi A, Landonio S, et al
    Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous daa failure.
    J Hepatol. 2019 Aug 6. pii: S0168-8278(19)30461.
    PubMed     Text format     Abstract available


  4. ROSSI C, Jeong D, Wong S, McKee G, et al
    Sustained Virologic Response from Interferon-based Hepatitis C regimes IS associated with Reduced risk of Extrahepatic Manifestations.
    J Hepatol. 2019 Aug 6. pii: S0168-8278(19)30462.
    PubMed     Text format     Abstract available


    July 2019
  5. DHIMAN RK, Grover GS, Premkumar M, Taneja S, et al
    Decentralized Care with Generic Direct-Acting Antivirals in the Management of Chronic Hepatitis C in a Public Health Care Setting.
    J Hepatol. 2019 Jul 17. pii: S0168-8278(19)30414.
    PubMed     Text format     Abstract available


  6. AREGAY A, Sekyere SO, Deterding K, Port K, et al
    Elimination of Hepatitis C Virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.
    J Hepatol. 2019 Jul 8. pii: S0168-8278(19)30397.
    PubMed     Text format     Abstract available


  7. COMARMOND C, Lorin V, Marques C, Maciejewski-Duval A, et al
    TLR9 Signaling in HCV-Associated Atypical Memory B Cells Triggers Th1 and Rheumatoid Factor Autoantibody Responses.
    J Hepatol. 2019 Jul 4. pii: S0168-8278(19)30401.
    PubMed     Text format     Abstract available


    June 2019
  8. LLANERAS J, Riveiro-Barciela M, Lens S, Diago M, et al
    Effectiveness and Safety of Sofosbuvir/Velpatasvir/ Voxilaprevir in Patients with Chronic Hepatitis C Previously Treated with DAAs.
    J Hepatol. 2019 Jun 13. pii: S0168-8278(19)30345.
    PubMed     Text format     Abstract available


  9. BORGIA SM, Dearden J, Yoshida EM, Shafran SD, et al
    Sofosbuvir/Velpatasvir for 12 Weeks in Hepatitis C Virus-Infected Patients with End-Stage Renal Disease Undergoing Dialysis.
    J Hepatol. 2019 Jun 10. pii: S0168-8278(19)30343.
    PubMed     Text format     Abstract available


  10. SAPENA V, Rios J, Torres F, Marino Z, et al
    Reply to: "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response".
    J Hepatol. 2019 Jun 7. pii: S0168-8278(19)30280.
    PubMed     Text format    


  11. WILSON E, Covert E, Hoffmann J, Comstock E, et al
    A Pilot Study of Safety and Efficacy of HCV Retreatment with sofosbuvir/velpatasvir/voxilaprevir in Patients With or Without HIV (RESOLVE STUDY).
    J Hepatol. 2019 Jun 4. pii: S0168-8278(19)30307.
    PubMed     Text format     Abstract available


    May 2019
  12. POL S, Fontaine H, Carrat F
    Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response.
    J Hepatol. 2019 May 23. pii: S0168-8278(19)30186.
    PubMed     Text format    


  13. EVON DM, Sarkar S, Amador J, Lok AS, et al
    Patient-reported symptoms during and after direct acting antiviral therapies for chronic hepatitis C: The PROP UP Study.
    J Hepatol. 2019 May 13. pii: S0168-8278(19)30278.
    PubMed     Text format     Abstract available


  14. JI F, Yeo YH, Wei MT, Ogawa E, et al
    Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.
    J Hepatol. 2019 May 13. pii: S0168-8278(19)30279.
    PubMed     Text format     Abstract available


  15. ALAVI M, Law MG, Valerio H, Grebely J, et al
    Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    J Hepatol. 2019 May 9. pii: S0168-8278(19)30275.
    PubMed     Text format     Abstract available


    April 2019
  16. HONG J, Kushner T, Dieterich D, Garry D, et al
    Reducing mother-to-child transmission of HCV: Is it attainable with a multidisciplinary approach?
    J Hepatol. 2019 Apr 24. pii: S0168-8278(19)30079.
    PubMed     Text format    


  17. WRENSCH F, Keck ZY, Foung SKH, Baumert TF, et al
    Learning from a clinical cohort for HCV vaccine development.
    J Hepatol. 2019 Apr 13. pii: S0168-8278(19)30224.
    PubMed     Text format    


  18. MOUNA L, Rossignol E, Tateo M, Coilly A, et al
    Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence: Prophylaxis makes the difference.
    J Hepatol. 2019 Apr 6. pii: S0168-8278(19)30136.
    PubMed     Text format    


  19. CABIBBO G, Celsa C, Calvaruso V, Petta S, et al
    Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    J Hepatol. 2019 Apr 5. pii: S0168-8278(19)30221.
    PubMed     Text format     Abstract available


  20. UMUTESI G, Shumbusho F, Kateera F, Serumondo J, et al
    Rwanda launches a 5-year national hepatitis C elimination plan: A landmark in sub-Saharan Africa.
    J Hepatol. 2019 Apr 1. pii: S0168-8278(19)30179.
    PubMed     Text format    


    March 2019
  21. DENG L, Jiang W, Wang X, Merz A, et al
    Syntenin regulates Hepatitis C virus sensitivity to neutralizing antibody by promoting E2 secretion through exosomes.
    J Hepatol. 2019 Mar 14. pii: S0168-8278(19)30147.
    PubMed     Text format     Abstract available


  22. WYLES D, Weiland O, Yao B, Weilert F, et al
    Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection.
    J Hepatol. 2019 Mar 8. pii: S0168-8278(19)30078.
    PubMed     Text format    


    February 2019
  23. MERAT SJ, Bru C, van de Berg D, Molenkamp R, et al
    Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance.
    J Hepatol. 2019 Feb 20. pii: S0168-8278(19)30128.
    PubMed     Text format     Abstract available


  24. MORGAN FREIMAN J, Wang J, Easterbrook PJ, Robert Horsburgh C, et al
    Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: analysis of a global dataset.
    J Hepatol. 2019 Feb 20. pii: S0168-8278(19)30125.
    PubMed     Text format     Abstract available


  25. BANDA DH, Perin PM, Brown RJP, Todt D, et al
    A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors.
    J Hepatol. 2019 Feb 12. pii: S0168-8278(19)30110.
    PubMed     Text format     Abstract available


  26. KEMMING J, Reeves E, Nitschke K, Widmeier V, et al
    ERAP1 allotypes impact the epitope repertoire of virus-specific CD8(+) T cell responses in acute hepatitis C virus infection.
    J Hepatol. 2019 Feb 12. pii: S0168-8278(19)30111.
    PubMed     Text format     Abstract available


    January 2019
  27. MARINO Z, Darnell A, Lens S, Sapena V, et al
    Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules.
    J Hepatol. 2019 Jan 23. pii: S0168-8278(19)30015.
    PubMed     Text format     Abstract available


  28. PAPALUCA T, McDonald L, Craigie A, Gibson A, et al
    Outcomes of treatment for hepatitis C in prisoners using a nurse-led, state-wide model of care.
    J Hepatol. 2019 Jan 14. pii: S0168-8278(19)30024.
    PubMed     Text format     Abstract available


    December 2018
  29. DENOLLY S, Granier C, Fontaine N, Pozzetto B, et al
    A serum protein factor mediates maturation and apoB-association of HCV particles in the extracellular milieu.
    J Hepatol. 2018 Dec 13. pii: S0168-8278(18)32619.
    PubMed     Text format     Abstract available


  30. BOEREKAMPS A, Vanwolleghem T, van der Valk M, van den Berk GE, et al
    8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study).
    J Hepatol. 2018 Dec 5. pii: S0168-8278(18)32516.
    PubMed     Text format    


    November 2018
  31. MODIN L, Arshad A, Wilkes B, Benselin J, et al
    Epidemiology and natural history of hepatitis C virus infection among children and young people.
    J Hepatol. 2018 Nov 26. pii: S0168-8278(18)32545.
    PubMed     Text format     Abstract available


  32. VAN SEYEN M, Smolders EJ, van Wijngaarden P, Drenth JPH, et al
    Successful HCV treatment of patients on contraindicated anti-epileptic drugs: Role of drug level monitoring.
    J Hepatol. 2018 Nov 22. pii: S0168-8278(18)32492.
    PubMed     Text format    


  33. D'AMBROSIO R, Pasulo L, Puoti M, Vinci M, et al
    Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in 723 patients with chronic hepatitis C.
    J Hepatol. 2018 Nov 22. pii: S0168-8278(18)32543.
    PubMed     Text format     Abstract available


  34. COSTA R, Todt D, Zapatero-Belinchon F, Schenk C, et al
    SEC14L2, a lipid-binding protein, regulate HCV replication in culture with inter- and intra- genotype variations.
    J Hepatol. 2018 Nov 22. pii: S0168-8278(18)32544.
    PubMed     Text format     Abstract available


  35. STAMM LM, Brainard DM, McHutchison JG
    Sofosbuvir/Velpatasvir for Patients with Chronic Genotype 3 HCV Infection with Compensated Cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018.
    J Hepatol. 2018 Nov 13. pii: S0168-8278(18)32528.
    PubMed     Text format    


  36. KHERA T, Behrendt P, Bankwitz D, Brown RJP, et al
    Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants.
    J Hepatol. 2018 Nov 12. pii: S0168-8278(18)32527.
    PubMed     Text format     Abstract available



  37. Reply to: "Sofosbuvir/Velpatasvir for Patients with Chronic Genotype 3 HCV Infection with Compensated Cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018".
    J Hepatol. 2018 Nov 12. pii: S0168-8278(18)32529.
    PubMed     Text format    


  38. PHAM LV, Jensen SB, Fahnoe U, Pedersen MS, et al
    HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape.
    J Hepatol. 2018 Nov 2. pii: S0168-8278(18)32515.
    PubMed     Text format     Abstract available


    October 2018
  39. JENNY I, Gregory JD, Beth C, Philip C, et al
    Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
    J Hepatol. 2018 Oct 24. pii: S0168-8278(18)32494.
    PubMed     Text format     Abstract available


  40. IOANNOU GN
    Reply to: "Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment".
    J Hepatol. 2018 Oct 19. pii: S0168-8278(18)32445.
    PubMed     Text format    


  41. JI F, Yeo YH, He C, Li J, et al
    Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment.
    J Hepatol. 2018 Oct 15. pii: S0168-8278(18)32390.
    PubMed     Text format    


  42. NISHIBATAKE KINOSHITA M, Minami T, Tateishi R, Wake T, et al
    Impact of direct-acting antivirals on early recurrence of HCV-related HCC: comparison with interferon-based therapy.
    J Hepatol. 2018 Oct 15. pii: S0168-8278(18)32454.
    PubMed     Text format     Abstract available


  43. NEWSUM AM, Molenkamp R, van der Meer JT, Rebers SP, et al
    Persistence of NS5B-S282T, a sofosbuvir resistance-associated substitution, in a HIV/HCV-coinfected MSM with risk of onward transmission.
    J Hepatol. 2018;69:968-970.
    PubMed     Text format    


  44. BERENGUER M, de la Rosa Rodriguez G, Dominguez-Gil B
    Significant impact of new oral therapies against HCV on the waiting list for liver transplantation in Spain.
    J Hepatol. 2018;69:966-968.
    PubMed     Text format    


  45. DEUFFIC-BURBAN S, Huneau A, Verleene A, Brouard C, et al
    Assessing the cost-effectiveness of hepatitis C screening strategies in France.
    J Hepatol. 2018;69:785-792.
    PubMed     Text format     Abstract available


    September 2018
  46. BELPERIO PS, Shahoumian TA, Loomis TP, Mole LA, et al
    Real-world Effectiveness of Daclatasvir plus Sofosbuvir and Velpatasvir/Sofosbuvir in Hepatitis C Genotype 2 and 3.
    J Hepatol. 2018 Sep 25. pii: S0168-8278(18)32392.
    PubMed     Text format     Abstract available


    August 2018
  47. ROSSI C, Butt Z, Wong S, Buxton J, et al
    Hepatitis C Virus Reinfection after Successful Treatment with Direct-Acting Antiviral Therapy in a Large Population-Based Cohort.
    J Hepatol. 2018 Aug 21. pii: S0168-8278(18)32288.
    PubMed     Text format     Abstract available


  48. IOANNOU GN, Green PK, Beste LA, Mun EJ, et al
    Development of Models Estimating the Risk of Hepatocellular Carcinoma After Antiviral Treatment for Hepatitis C.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32287.
    PubMed     Text format     Abstract available


  49. TERRAULT NA, Pageaux GP
    A changing landscape of liver transplantation: King HCV is dethroned, ALD and NAFLD take over!
    J Hepatol. 2018 Aug 10. pii: S0168-8278(18)32276.
    PubMed     Text format    


  50. SARRAZIN C, Cooper CL, Manns MP, Reddy KR, et al
    No Impact of Resistance Associated Substitutions on the Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir for 12 Weeks in HCV DAA-experienced Patients.
    J Hepatol. 2018 Aug 8. pii: S0168-8278(18)32279.
    PubMed     Text format     Abstract available


  51. HERZER K, Gerken G, Kroy D, Tacke F, et al
    Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany.
    J Hepatol. 2018 Aug 6. pii: S0168-8278(18)32179.
    PubMed     Text format    


    July 2018
  52. VERMEHREN J, Park JS, Jacobson I, Zeuzem S, et al
    Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection.
    J Hepatol. 2018 Jul 10. pii: S0168-8278(18)32181.
    PubMed     Text format     Abstract available


  53. GRAUPERA I, Lammert F
    Screening is caring: Community-based non-invasive diagnosis and treatment strategies for hepatitis C to reduce liver disease burden.
    J Hepatol. 2018 Jul 5. pii: S0168-8278(18)32125.
    PubMed     Text format    


    June 2018
  54. MARSHALL AD, Pawlotsky JM, Lazarus JV, Aghemo A, et al
    The removal of DAA restrictions in Europe - one step closer to eliminating HCV as a major public health threat.
    J Hepatol. 2018 Jun 27. pii: S0168-8278(18)32169.
    PubMed     Text format     Abstract available


  55. BELLI LS, Perricone G, Adam R, Cortesi PA, et al
    Impact of DAAs on liver transplantation: major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.
    J Hepatol. 2018 Jun 22. pii: S0168-8278(18)32163.
    PubMed     Text format     Abstract available


  56. ROCA SUAREZ AA, Baumert TF, Lupberger J
    Beyond viral dependence: The pathological consequences of HCV-induced EGF signaling.
    J Hepatol. 2018 Jun 21. pii: S0168-8278(18)32118.
    PubMed     Text format    


  57. FORNS X, Sarrazin C
    Treatment of chronic hepatitis C.
    J Hepatol. 2018 Jun 8. pii: S0168-8278(18)32019.
    PubMed     Text format    


  58. AGARWAL K, Castells L, Mullhaupt B, Rosenberg WMC, et al
    Sofosbuvir/Velpatasvir for 12 Weeks in Genotype 1-4 HCV-Infected Liver Transplant Recipients.
    J Hepatol. 2018 Jun 7. pii: S0168-8278(18)32124.
    PubMed     Text format     Abstract available


    May 2018
  59. OJHA RP, Steyerberg EW
    Real-world data on antiviral treatments for hepatitis C virus infections: Can we define intention to treat or per protocol analyses?
    J Hepatol. 2018 May 26. pii: S0168-8278(18)31980.
    PubMed     Text format    


  60. CHEVALIEZ S, Pawlotsky JM
    New virological tools for screening, diagnosis and monitoring of hepatitis B and C in resource-limited settings.
    J Hepatol. 2018 May 22. pii: S0168-8278(18)32063.
    PubMed     Text format     Abstract available


  61. BUGGISCH P, Zeuzem S
    Real-world effectiveness of 8 weeks treatment with ledipasvir/sofosbuvir in chronic hepatitis C.
    J Hepatol. 2018 May 11. pii: S0168-8278(18)32051.
    PubMed     Text format     Abstract available


    April 2018
  62. BLOOM S, Kemp W, Nicoll A, Roberts SK, et al
    Liver Stiffness measurement in the primary care setting detects high rates of advanced fibrosis and predicts liver related events in hepatitis C.
    J Hepatol. 2018 Apr 27. pii: S0168-8278(18)32023.
    PubMed     Text format     Abstract available


  63. GROEPPER C, Rufinatscha K, Schroder N, Stindt S, et al
    HCV modifies EGF signalling and upregulates production of CXCR2 ligands: role in inflammation and antiviral immune response.
    J Hepatol. 2018 Apr 26. pii: S0168-8278(18)32013.
    PubMed     Text format     Abstract available



  64. EASL Recommendations on Treatment of Hepatitis C 2018.
    J Hepatol. 2018 Apr 9. pii: S0168-8278(18)31968.
    PubMed     Text format    


  65. ABDEL-MONEIM A, Aboud A, Abdel-Gabbar M, Zanaty MI, et al
    A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure.
    J Hepatol. 2018 Apr 3. pii: S0168-8278(18)30174.
    PubMed     Text format    


  66. NAKAO Y, Hashimoto S, Abiru S, Komori A, et al
    Rapidly growing, moderately differentiated HCC: A clinicopathological characteristic of HCC occurrence after IFN-free DAA therapy?
    J Hepatol. 2018;68:854-855.
    PubMed     Text format    


    March 2018
  67. ROMANO A, Angeli P, Piovesan S, Noventa F, et al
    "Newly diagnosed Hepatocellular Carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study".
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30172.
    PubMed     Text format     Abstract available


  68. PUOTI M, Foster GR, Wang S, Mutimer D, et al
    High SVR12 with 8-week and 12-week Glecaprevir/Pibrentasvir: Integrated Analysis of HCV Genotype 1-6 Patients Without Cirrhosis.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30165.
    PubMed     Text format     Abstract available


  69. PETTA S, Adinolfi LE, Fracanzani AL, Rini F, et al
    Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis.
    J Hepatol. 2018 Mar 2. pii: S0168-8278(18)30132.
    PubMed     Text format     Abstract available


  70. TOYODA H, Kumada T, Tada T, Mizuno K, et al
    Imaging basis of AFP and WFA(+)M2BP as indicators of the risk of HCC after SVR.
    J Hepatol. 2018;68:606-607.
    PubMed     Text format    


  71. CAMMA C, Leandro G
    Direct antiviral agents and risk of HCC: Waiting for Godot.
    J Hepatol. 2018;68:614-616.
    PubMed     Text format    


    February 2018
  72. CRESPO G, Trota N, Londono MC, Mauro E, et al
    The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in wait-list composition.
    J Hepatol. 2018 Feb 23. pii: S0168-8278(18)30129.
    PubMed     Text format     Abstract available


    January 2018
  73. LEMOINE M, Cooke GS
    The Egyptian hepatitis C programme: a model of HCV treatment intervention?
    J Hepatol. 2018 Jan 30. pii: S0168-8278(18)30068.
    PubMed     Text format    


  74. KARAMPATOU A, Han X, Kondili LA, Taliani G, et al
    Corrigendum to "Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV" [J Hepatol 68 (2018) 33-41].
    J Hepatol. 2018 Jan 20. pii: S0168-8278(18)30013.
    PubMed     Text format    


  75. DA SILVA FILIPE A, Sreenu V, Hughes J, Aranday-Cortes E, et al
    Reply to: No effect of resistance-associated substitutions in patients with rare HCV subtypes following treatment with sofosbuvir-containing regimens.
    J Hepatol. 2018 Jan 12. pii: S0168-8278(18)30014.
    PubMed     Text format    


  76. LEVADA K, Guldiken N, Zhang X, Vella G, et al
    Hsp72 protects from liver injury via attenuation of hepatocellular death, oxidative stress and JNK-signaling.
    J Hepatol. 2018 Jan 10. pii: S0168-8278(18)30008.
    PubMed     Text format     Abstract available


    December 2017
  77. SCHWARZINGER M, Rehm J, Mallet V
    "Who killed JR": chronic hepatitis C or alcohol use disorders?
    J Hepatol. 2017 Dec 30. pii: S0168-8278(17)32539.
    PubMed     Text format    


  78. ALAVI M, Law MG, Dore GJ
    Reply to: "Who killed JR": chronic hepatitis C or alcohol use disorders?
    J Hepatol. 2017 Dec 29. pii: S0168-8278(17)32538.
    PubMed     Text format    


  79. AMPUERO J, Jimeno C, Quiles R, Rosales JM, et al
    Impact of comorbidities on patients outcomes after interferon-free therapy-induced viral eradication in hepatitis.
    J Hepatol. 2017 Dec 27. pii: S0168-8278(17)32535.
    PubMed     Text format     Abstract available


  80. SCOTT N, Olafsson S, Gottfreethsson M, Tyrfingsson T, et al
    Modelling the elimination of hepatitis C as a public health threat in Iceland: a goal attainable by 2020.
    J Hepatol. 2017 Dec 20. pii: S0168-8278(17)32528.
    PubMed     Text format     Abstract available


  81. SODERHOLM J, Millbourn C, Busch K, Kovamees J, et al
    Higher risk of renal disease in chronic hepatitis C patients: antiviral therapy survival benefit in patients on hemodialysis.
    J Hepatol. 2017 Dec 9. pii: S0168-8278(17)32485.
    PubMed     Text format     Abstract available


  82. HELLARD M, Scott N, Sacks Davis R, Pedrana A, et al
    Achieving hepatitis C elimination in Europe - to treatment scale up and beyond.
    J Hepatol. 2017 Dec 9. pii: S0168-8278(17)32486.
    PubMed     Text format    


  83. ASSELAH T, Hassanein T, Waked I, Mansouri A, et al
    Eliminating Hepatitis C within Low Income Countries - the need to cure Genotypes 4, 5, 6.
    J Hepatol. 2017 Dec 8. pii: S0168-8278(17)32482.
    PubMed     Text format     Abstract available


  84. ELSHARKAWY A, Raziky ME, Akel WE, Saeed KE, et al
    Planning and prioritizing direct acting antivirals treatment for HCV patients in countries with limited resources: lessons from the Egyptian experience.
    J Hepatol. 2017 Dec 6. pii: S0168-8278(17)32478.
    PubMed     Text format     Abstract available


  85. OVREHUS ALH, Krarup H, Birkemose I, Holm DK, et al
    Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial.
    J Hepatol. 2017 Dec 6. pii: S0168-8278(17)32475.
    PubMed     Text format    


  86. HEZODE C, Reau N, Svarovskaia ES, Doehle BP, et al
    Resistance Analysis in Patients with Genotype 1-6 HCV Infection Treated with Sofosbuvir/Velpatasvir in the Phase 3 Studies.
    J Hepatol. 2017 Dec 5. pii: S0168-8278(17)32476.
    PubMed     Text format     Abstract available


    November 2017
  87. HUPA KL, Deterding K, Port K, Kimmann M, et al
    In Reply to: EASL RECOMMENDATIONS ON TREATMENT OF HEPATITIS C 2016 "Stomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C?"
    J Hepatol. 2017 Nov 21. pii: S0168-8278(17)32443.
    PubMed     Text format    


  88. INNES H, Barclay ST, Hayes PC, Fraser A, et al
    The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen.
    J Hepatol. 2017 Nov 15. pii: S0168-8278(17)32429.
    PubMed     Text format     Abstract available


  89. BUGGISCH P, Vermehren J, Mauss S, Gunther R, et al
    Real-world effectiveness of 8 weeks treatment with ledipasvir/sofosbuvir in chronic hepatitis C.
    J Hepatol. 2017 Nov 10. pii: S0168-8278(17)32431.
    PubMed     Text format     Abstract available


  90. CARRIERI MP, Protopopescu C, Marcellin F, Wittkop L, et al
    The impact of coffee consumption on fibrosis and steatosis in HIV-HCV co-infected patients.
    J Hepatol. 2017 Nov 2. pii: S0168-8278(17)32406.
    PubMed     Text format    


    October 2017
  91. MURCIA O, Carnicer F, Gomez-Escolar L, Miralles C, et al
    Direct antiviral agents against Hepatitis C virus: beneficial or harmful?
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32407.
    PubMed     Text format    


  92. POLLMANN J, Gotz JJ, Rupp D, Strauss O, et al
    Hepatitis C virus-induced natural killer cell proliferation involves monocyte-derived cells and the OX40/OX40L axis.
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32400.
    PubMed     Text format     Abstract available


  93. ALAVI M, Janjua NZ, Chong M, Grebely J, et al
    The contribution of alcohol-use disorder to decompensated cirrhosis among people with hepatitis C: an international study.
    J Hepatol. 2017 Oct 26. pii: S0168-8278(17)32398.
    PubMed     Text format     Abstract available


  94. LONDONO MC, Forns X, Pascasio JM
    Reply to: "Extended DAA indications for hepatitis C patients awaiting liver transplantation and further statistical considerations".
    J Hepatol. 2017 Oct 25. pii: S0168-8278(17)32385.
    PubMed     Text format    


  95. FRASER H, Martin NK, Brummer-Korvenkontio H, Carrieri P, et al
    Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe".
    J Hepatol. 2017 Oct 25. pii: S0168-8278(17)32387.
    PubMed     Text format     Abstract available


  96. AZAB M, Shah S, Liu X, Ukken J, et al
    Extended DAA indications for hepatitis C patients awaiting liver transplantation and further statistical considerations.
    J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32390.
    PubMed     Text format    


  97. HALFON P, Scholtes C, Izopet J, Larrat S, et al
    Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world.
    J Hepatol. 2017 Oct 4. pii: S0168-8278(17)32333.
    PubMed     Text format     Abstract available


    September 2017
  98. DI MAIO VC, Cento V, Aragri M, Paolucci S, et al
    Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: what are the chances for second-line regimens?
    J Hepatol. 2017 Sep 20. pii: S0168-8278(17)32288.
    PubMed     Text format    


  99. LIU X, Shen JJ, Jung Kim S, Lee YJ, et al
    Necessity of time series analysis and effects of direct-acting antivirals on HCV patients awaiting liver transplantation.
    J Hepatol. 2017 Sep 19. pii: S0168-8278(17)32290.
    PubMed     Text format    


  100. ESMAT G, Elbaz T, El Raziky M, Gomaa A, et al
    Effectiveness of ravidasvir plus sofosbuvir in interferon-naive and treated patients with chronic hepatitis c genotype-4.
    J Hepatol. 2017 Sep 18. pii: S0168-8278(17)32286.
    PubMed     Text format     Abstract available


  101. PRENNER S, Kulik L
    Reply to "Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma".
    J Hepatol. 2017 Sep 13. pii: S0168-8278(17)32283.
    PubMed     Text format    


  102. CARRIERI MP, Protopopescu C, Marcellin F, Rosellini S, et al
    Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients.
    J Hepatol. 2017 Sep 12. pii: S0168-8278(17)32211.
    PubMed     Text format     Abstract available


  103. FANGAZIO S, Camatta D, Minh MT, Ceriani E, et al
    Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma.
    J Hepatol. 2017 Sep 7. pii: S0168-8278(17)32280.
    PubMed     Text format    


  104. IOANNOU GN, Green PK, Berry K
    HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32273.
    PubMed     Text format     Abstract available


  105. KARAMPATOU A, Han X, Kondili LA, Taliani G, et al
    Premature ovarian senescence and high miscarriage rate impair fertility in women with hepatitis C virus infection.
    J Hepatol. 2017 Sep 4. pii: S0168-8278(17)32259.
    PubMed     Text format     Abstract available


    August 2017
  106. CALVARUSO V, Craxi A
    HBV recurrence after HCV clearance on DAAs: Sometimes They Come Back.
    J Hepatol. 2017 Aug 29. pii: S0168-8278(17)32256.
    PubMed     Text format    


  107. KRAMER L, Laurain A, Sultanik P, Tremeaux P, et al
    "Empirical" retreatment of patients with chronic hepatitis C who failed a first direct-acting antiviral-based regimen.
    J Hepatol. 2017 Aug 23. pii: S0168-8278(17)32251.
    PubMed     Text format    


  108. GARVEY P, Murphy N, Flanagan P, Brennan A, et al
    Disease Outcomes in a Cohort of Women Infected by Hepatitis C-Contaminated anti-D Immunoglobulin During 1970s.
    J Hepatol. 2017 Aug 23. pii: S0168-8278(17)32249.
    PubMed     Text format     Abstract available


  109. PASCASIO JM, Vinaixa C, Ferrer MT, Colmenero J, et al
    Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation.
    J Hepatol. 2017 Aug 22. pii: S0168-8278(17)32215.
    PubMed     Text format     Abstract available


  110. MELE D, Mantovani S, Oliviero B, Grossi G, et al
    Monocytes inhibit hepatitis C virus-induced TRAIL expression on CD56bright NK cells.
    J Hepatol. 2017 Aug 10. pii: S0168-8278(17)32203.
    PubMed     Text format     Abstract available


  111. DONATO MF, Invernizzi F, Rossi G, Iavarone M, et al
    Interferon-free therapy of hepatitis C during wait list and post-transplant risk of hepatocellular carcinoma recurrence.
    J Hepatol. 2017 Aug 10. pii: S0168-8278(17)32200.
    PubMed     Text format    


  112. WAZIRY R, Hajarizadeh B, Grebely J, Amin J, et al
    Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.
    J Hepatol. 2017 Aug 9. pii: S0168-8278(17)32199.
    PubMed     Text format     Abstract available


  113. DONG YANG J, Leise MD
    Reply to " Interferon-free therapy of hepatitis C during wait list and post transplant risk of hepatocellular carcinoma recurrence".
    J Hepatol. 2017 Aug 8. pii: S0168-8278(17)32201.
    PubMed     Text format    


  114. ZEUZEM S, Dvory-Sobol H, Brainard DM
    No Effect Of Resistance-Associated Substitutions In Patients With Rare HCV Subtypes Following Treatment With Sofosbuvir-Containing Regimens.
    J Hepatol. 2017 Aug 5. pii: S0168-8278(17)32191.
    PubMed     Text format    


  115. DA SILVA FILIPE A, Sreenu V, Hughes J, Aranday-Cortes E, et al
    Response to DAA Therapy in the NHS England Early Access Programme for Rare HCV Subtypes from Low and Middle Income Countries.
    J Hepatol. 2017 Aug 5. pii: S0168-8278(17)32195.
    PubMed     Text format    


    July 2017
  116. LAZARUS JV, Wiktor S, Colombo M, Thursz M, et al
    Micro-elimination - A path to global elimination of hepatitis C.
    J Hepatol. 2017 Jul 28. pii: S0168-8278(17)32141.
    PubMed     Text format    


  117. SUDA T, Shimakami T, Shirasaki T, Yamashita T, et al
    Reactivation of Hepatitis B Virus from an isolated Anti-HBc positive patient after eradication of Hepatitis C Virus with Direct-acting Antiviral Agents.
    J Hepatol. 2017 Jul 21. pii: S0168-8278(17)32158.
    PubMed     Text format    


  118. KOLLY P, Waidmann O, Vermehren J, Moreno C, et al
    Hepatocellular Carcinoma Recurrence after Direct Antiviral Agent Treatment: a European Multicentre Study.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32150.
    PubMed     Text format    


  119. SAMJI H, Yu A, Kuo M, Alavi M, et al
    Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development.
    J Hepatol. 2017 Jul 3. pii: S0168-8278(17)32133.
    PubMed     Text format     Abstract available


    June 2017

  120. Response to the Cochrane Systematic Review on DAA-Based Treatment of Chronic Hepatitis C.
    J Hepatol. 2017 Jun 29. pii: S0168-8278(17)32129.
    PubMed     Text format    


  121. POORDAD F, Nelson DR, Feld JJ, Fried MW, et al
    Safety of the 2D/3D direct acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - a pooled analysis.
    J Hepatol. 2017 Jun 20. pii: S0168-8278(17)32083.
    PubMed     Text format     Abstract available


  122. NAGATA H, Nakagawa M, Asahina Y, Sato A, et al
    Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C.
    J Hepatol. 2017 Jun 13. pii: S0168-8278(17)32070.
    PubMed     Text format     Abstract available


  123. SUSSER S, Dietz J, Schlevogt B, Zuckerman E, et al
    Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras.
    J Hepatol. 2017 Jun 12. pii: S0168-8278(17)32069.
    PubMed     Text format     Abstract available


    May 2017
  124. PEMBROKE T, Deschenes M, Lebouche B, Benmassaoud A, et al
    Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32047.
    PubMed     Text format     Abstract available


  125. ANDREASSON K, Waldenstrom J, Westin J, Norrgren H, et al
    JHEPAT-D-17-00297 R1: Cartilage oligomeric matrix protein associates with hepatic inflammation and fibrosis in hepatitis C virus infection.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32044.
    PubMed     Text format    


  126. COLPITTS CC, Baumert TF
    SCARB1 variants and HCV infection: Host susceptibility is lost in translation.
    J Hepatol. 2017 May 3. pii: S0168-8278(17)30255.
    PubMed     Text format    


    April 2017
  127. BANKWITZ D, Doepke M, Hueging K, Weller R, et al
    Maturation of secreted HCV particles by incorporation of secreted apoE protects from antibodies by enhancing infectivity.
    J Hepatol. 2017 Apr 21. pii: S0168-8278(17)30251.
    PubMed     Text format     Abstract available


  128. KAWAGISHI N, Suda G, Onozawa M, Kimura M, et al
    Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection.
    J Hepatol. 2017 Apr 21. pii: S0168-8278(17)30249.
    PubMed     Text format     Abstract available


  129. BRUNO S, Maisonneuve P
    Response to the letter regarding the manuscript "Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population".
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30216.
    PubMed     Text format    


  130. HALLAGER S, Ladelund S, Weis N
    Methodological considerations when calculating person time at risk for patients with chronic hepatitis C undergoing antiviral treatment.
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30218.
    PubMed     Text format    


  131. KWO PY, Poordad F, Asatryan A, Wang S, et al
    Glecaprevir and Pibrentasvir Yield High response Rates in Patients with HCV Genotype 1-6 without Cirrhosis.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30211.
    PubMed     Text format     Abstract available


  132. THONS C, Senff T, Hydes TJ, Manser AR, et al
    HLA-Bw4 80(T) and multiple HLA-Bw4 copies combined with KIR3DL1 associate with spontaneous clearance of HCV infection in people who inject drugs.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30213.
    PubMed     Text format     Abstract available


  133. VAN SANTEN DK, Van Der Helm JJ, Del Amo J, Meyer L, et al
    Lack of decline in Hepatitis C Virus incidence among HIV-positive men who have sex with men during 1990-2014.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30209.
    PubMed     Text format     Abstract available


  134. ZIMMERMANN R, Kollan C, Ingiliz P, Mauss S, et al
    Reply to "Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030".
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30204.
    PubMed     Text format    


  135. DORE GJ, Grebely J
    Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030.
    J Hepatol. 2017 Apr 11. pii: S0168-8278(17)30206.
    PubMed     Text format    


  136. TUMINO N, Casetti R, Fabbri G, Cimini E, et al
    In HIV/HCV co-infected patients T regulatory and myeloid derived suppressor cells persist after successful treatment with directly acting antivirals.
    J Hepatol. 2017 Apr 11. pii: S0168-8278(17)30207.
    PubMed     Text format    


  137. HASSON H, Merli M, Messina E, Bhoori S, et al
    Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals.
    J Hepatol. 2017 Apr 11. pii: S0168-8278(17)30203.
    PubMed     Text format     Abstract available


  138. LANGHANS B
    Reply to "In HIV/HCV co-infected patients T regulatory and myeloid derived suppressor cells persist after successful treatment with directly acting antivirals".
    J Hepatol. 2017 Apr 9. pii: S0168-8278(17)30205.
    PubMed     Text format    


  139. SCHWARZINGER M, Baillot S, Yazdanpanah PY, Rehm PJ, et al
    Contribution of Alcohol Use Disorders on the Burden of Chronic Hepatitis C in France, 2008-2013: A Nationwide Retrospective Cohort Study.
    J Hepatol. 2017 Apr 7. pii: S0168-8278(17)30202.
    PubMed     Text format     Abstract available


    March 2017
  140. WESTHAUS S, Deest M, Nguyen AT, Stanke F, et al
    Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load.
    J Hepatol. 2017 Mar 28. pii: S0168-8278(17)30184.
    PubMed     Text format     Abstract available


  141. WELZEL T, Bhardwaj N, Hedskog C, Chodavarapu K, et al
    Global Epidemiology of HCV Subtypes and Resistance-associated Substitutions Evaluated by Sequencing-Based Subtype Analyses.
    J Hepatol. 2017 Mar 23. pii: S0168-8278(17)30148.
    PubMed     Text format     Abstract available


  142. BERTUCCIO P, Turati F, Carioli G, Rodriguez T, et al
    Global Trends and Predictions in Hepatocellular Carcinoma Mortality.
    J Hepatol. 2017 Mar 20. pii: S0168-8278(17)30145.
    PubMed     Text format     Abstract available


  143. BELLI LS, Duvoux C, Berg T, Strazzabosco M, et al
    ELITA consensus statements on use of DAAs in liver transplant candidates and recipients.
    J Hepatol. 2017 Mar 18. pii: S0168-8278(17)30140.
    PubMed     Text format     Abstract available


  144. MARTIN NK, Vickerman P, Hickman M
    How to eliminate HCV infection by antiviral treatment.
    J Hepatol. 2017 Mar 17. pii: S0168-8278(17)30142.
    PubMed     Text format    


  145. BESTE LA, Green PK, Berry K, Kogut MJ, et al
    Effectiveness of hepatitis c antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma.
    J Hepatol. 2017 Mar 3. pii: S0168-8278(17)30126.
    PubMed     Text format     Abstract available


    February 2017
  146. PIROTH L, Wittkop L, Lacombe K, Rosenthal E, et al
    Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-coinfected patients - French ANRS CO13 HEPAVIH cohort.
    J Hepatol. 2017 Feb 21. pii: S0168-8278(17)30107.
    PubMed     Text format     Abstract available


  147. RAMOS-CASALS M, Zignego AL, Ferri C, Brito-Zeron P, et al
    Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection.
    J Hepatol. 2017 Feb 17. pii: S0168-8278(17)30105.
    PubMed     Text format     Abstract available


  148. OLIVIERO B, Mantovani S, Varchetta S, Mele D, et al
    Hepatitis C virus-Induced NK Cell Activation Causes Metzincin-Mediated CD16 Cleavage and Impaired Antibody-Dependent Cytotoxicity.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30069.
    PubMed     Text format     Abstract available


  149. CABIBBO G, Petta S, Barbara M, Attardo S, et al
    Hepatic Decompensation is the Major Driver of Death In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30070.
    PubMed     Text format     Abstract available


  150. ZENG QL, Xu GH, Zhang JY, Li W, et al
    Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: a real-life observational study.
    J Hepatol. 2017 Feb 8. pii: S0168-8278(17)30060.
    PubMed     Text format     Abstract available


  151. ZIMMERMANN R, Kollan C, Ingiliz P, Mauss S, et al
    Real-world treatment for chronic hepatitis C infection in Germany. Analyses from drug prescription data, 2010 - 2015.
    J Hepatol. 2017 Feb 8. pii: S0168-8278(17)30059.
    PubMed     Text format     Abstract available


  152. CALLEJA JL, Crespo J, Rincon D, Ruiz-Antoran B, et al
    Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real world cohort.
    J Hepatol. 2017 Feb 8. pii: S0168-8278(17)30063.
    PubMed     Text format     Abstract available


  153. GREBELY J, Swan T, Hickman M, Bruneau J, et al
    Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C.
    J Hepatol. 2017 Feb 3. pii: S0168-8278(17)30054.
    PubMed     Text format    


  154. PAWLOTSKY JM
    Consistent advice for people who inject drugs in the 2016 EASL Recommendations on treatment of hepatitis C.
    J Hepatol. 2017 Feb 3. pii: S0168-8278(17)30055.
    PubMed     Text format    


  155. PRENNER S, VanWagner LB, Flamm SL, Salem R, et al
    Hepatocellular Carcinoma Decreases the Chance of Successful Hepatitis C Virus Therapy with Direct-Acting Antivirals.
    J Hepatol. 2017 Feb 1. pii: S0168-8278(17)30053.
    PubMed     Text format     Abstract available


    January 2017
  156. FARQUHAR MJ, Humphreys IS, Rudge SA, Wilson GK, et al
    Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.
    J Hepatol. 2017 Jan 23. pii: S0168-8278(17)30013.
    PubMed     Text format     Abstract available


  157. ZEUZEM S, Mizokami M, Pianko S, Mangia A, et al
    NS5A Resistance-Associated Substitutions in Patients with Genotype 1 Hepatitis C Virus: Prevalence and Effect on Treatment Outcome.
    J Hepatol. 2017 Jan 17. pii: S0168-8278(17)30011.
    PubMed     Text format     Abstract available


  158. KLAG T, Dietz J, Werner CR, Schwarz JM, et al
    Hepatitis C "true" late relapse beyond 48 weeks of sustained virologic response after direct acting antiviral therapy.
    J Hepatol. 2017 Jan 9. pii: S0168-8278(17)30006.
    PubMed     Text format    


    December 2016
  159. LANGHANS B, Dieter Nischalke H, Kramer B, Hausen A, et al
    Increased peripheral cd4+ regulatory t cells persist after successful direct-acting antiviral treatment of chronic hepatitis C.
    J Hepatol. 2016 Dec 28. pii: S0168-8278(16)30752.
    PubMed     Text format     Abstract available


  160. FERNANDEZ I, Munoz-Gomez R, Pascasio JM, Baliellas C, et al
    Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis c.
    J Hepatol. 2016 Dec 27. pii: S0168-8278(16)30753.
    PubMed     Text format     Abstract available


  161. VUKOTIC R, Conti F, Andreone P
    Hepatitis C virus eradication in elderly: The challenge worth a long-life elixir?
    J Hepatol. 2016 Dec 21. pii: S0168-8278(16)30745.
    PubMed     Text format    


  162. MANGIA A, Susser S, Piazzolla V, Agostinacchio E, et al
    Sofosbuvir and Ribavirin for genotype 2 HCV infected patients with cirrhosis: a real life experience.
    J Hepatol. 2016 Dec 10. pii: S0168-8278(16)30707.
    PubMed     Text format     Abstract available


  163. WYLES D, Dvory-Sobol H, Svarovskaia Doehle ES, Martin R, et al
    Post-Treatment Resistance Analysis of Hepatitis C Virus from Phase 2 and 3 Clinical Trials of Ledipasvir/ Sofosbuvir.
    J Hepatol. 2016 Dec 3. pii: S0168-8278(16)30699.
    PubMed     Text format     Abstract available


    November 2016
  164. NOTARPAOLO A, Layese R, Magistri P, Gambato M, et al
    Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    J Hepatol. 2016 Nov 26. pii: S0168-8278(16)30688.
    PubMed     Text format     Abstract available


  165. TOYODA H, Kumada T, Tada T, Shimada N, et al
    Efficacy and Tolerability of an IFN-free Regimen with DCV/ASV for Elderly Patients Infected with HCV Genotype 1B.
    J Hepatol. 2016 Nov 24. pii: S0168-8278(16)30686.
    PubMed     Text format     Abstract available


  166. HELLARD M, Pedrana A, Scott N
    Targeted direct-acting antiviral treatment for chronic hepatitis C: a financial reality or an obstacle to elimination?
    J Hepatol. 2016 Nov 21. pii: S0168-8278(16)30680.
    PubMed     Text format    


  167. TSAI PC, Huang CF, Yu ML
    Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: issue of tie interval between HCC treatment and antiviral therapy.
    J Hepatol. 2016 Nov 10. pii: S0168-8278(16)30646.
    PubMed     Text format    


  168. JANJUA NZ, Chong M, Kuo M, Woods R, et al
    Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    J Hepatol. 2016 Nov 3. pii: S0168-8278(16)30637.
    PubMed     Text format     Abstract available


  169. FALADE-NWULIA O, Sulkowski M
    The HCV care continuum does not end with cure: A call to arms for the prevention of reinfection.
    J Hepatol. 2016 Nov 2. pii: S0168-8278(16)30636.
    PubMed     Text format    


    October 2016
  170. VAN DER MEER AJ, Feld JJ, Hofer H, Almasio PL, et al
    Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
    J Hepatol. 2016 Oct 22. pii: S0168-8278(16)30582.
    PubMed     Text format     Abstract available


  171. DEUFFIC-BURBAN S, Boursier J, Leroy V, Yazdanpanah Y, et al
    Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis?
    J Hepatol. 2016 Oct 12. pii: S0168-8278(16)30568.
    PubMed     Text format     Abstract available


  172. ROSS DB, Belperio PS, Chartier M, Backus LI, et al
    Hepatitis C Testing in U.S. Veterans Born 1945-1965: An Update.
    J Hepatol. 2016 Oct 5. pii: S0168-8278(16)30557.
    PubMed     Text format    


  173. JUSTICE AC, Esserman D, Sarkar S, Levin FL, et al
    Reply to: "Disparities in Hepatitis C Testing in U.S. Veterans Born 1945-1965".
    J Hepatol. 2016 Oct 4. pii: S0168-8278(16)30558.
    PubMed     Text format    


  174. VAN DER MEER AJ, Berenguer M
    Reversion of disease manifestations after HCV eradication.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  175. CACOUB P, Desbois AC, Isnard-Bagnis C, Rocatello D, et al
    Hepatitis C virus infection and chronic kidney disease: Time for reappraisal.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  176. MAASOUMY B, Vermehren J
    Diagnostics in hepatitis C: The end of response-guided therapy?
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  177. EASTERBROOK PJ
    Who to test and how to test for chronic hepatitis C infection - 2016 WHO testing guidance for low- and middle-income countries.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  178. MIDGARD H, Weir A, Palmateer N, Lo Re V 3rd, et al
    HCV epidemiology in high-risk groups and the risk of reinfection.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  179. HEIM MH, Bochud PY, George J
    Host - hepatitis C viral interactions: The role of genetics.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  180. BUKH J
    The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  181. MORADPOUR D, Grakoui A, Manns MP
    Future landscape of hepatitis C research - Basic, translational and clinical perspectives.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  182. YOUNOSSI ZM, Birerdinc A, Henry L
    Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  183. FORNS X, Berg T
    Hepatitis C virus - A teacher of clinical research, cell biology and immunology.
    J Hepatol. 2016;65.
    PubMed     Text format    


    September 2016
  184. INGILIZ P, Martin TC, Rodger A, Stellbrink HJ, et al
    HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe.
    J Hepatol. 2016 Sep 17. pii: S0168-8278(16)30505.
    PubMed     Text format     Abstract available



  185. EASL Recommendations on Treatment of Hepatitis C 2016.
    J Hepatol. 2016 Sep 12. pii: S0168-8278(16)30489.
    PubMed     Text format    


  186. POL S, Bourliere M, Lucier S, Hezode C, et al
    Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
    J Hepatol. 2016 Sep 10. pii: S0168-8278(16)30486.
    PubMed     Text format     Abstract available


    July 2016
  187. NAULT JC, Colombo M
    Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution.
    J Hepatol. 2016 Jul 11. pii: S0168-8278(16)30327.
    PubMed     Text format    


    May 2016
  188. BELLI LS, Berenguer M, Cortesi PA, Strazzabosco M, et al
    DELISTING OF LIVER TRANSPLANT CANDIDATES WITH CHRNIC HEPATITIC C AFTER VIRAL ERADICATION: A EUROPEAN STUDY.
    J Hepatol. 2016 May 17. pii: S0168-8278(16)30196.
    PubMed     Text format     Abstract available


  189. PADEGIMAS A, Forde KA, Goldberg LR, Birati EY, et al
    Myo-pericarditis secondary to ledipasvir-sofosbuvir therapy.
    J Hepatol. 2016;64:1196-8.
    PubMed     Text format    


    January 2016
  190. YOUNOSSI ZM, Stepanova M, Estep M, Negro F, et al
    Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin.
    J Hepatol. 2016;64:29-36.
    PubMed     Text format     Abstract available


    September 2015
  191. YAN M, Ha J, Aguilar M, Bhuket T, et al
    Birth Cohort-Specific Disparities in Hepatocellular Carcinoma Stage at Diagnosis, Treatment, and Long-term Survival.
    J Hepatol. 2015 Sep 16. pii: S0168-8278(15)00623.
    PubMed     Text format     Abstract available


    August 2015
  192. GRANCINI V, Trombetta M, Lunati ME, Zimbalatti D, et al
    Contribution of beta-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: role of severity of liver disease.
    J Hepatol. 2015 Aug 19. pii: S0168-8278(15)00553.
    PubMed     Text format     Abstract available


  193. HUNG GY, Horng JL, Yen HJ, Lee CY, et al
    Changing Incidence Patterns of Hepatocellular Carcinoma Among Age Groups in Taiwan.
    J Hepatol. 2015 Aug 6. pii: S0168-8278(15)00534.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: